


5

CLAIMS

What is claimed is:

1. A compound comprising



or a pharmaceutically acceptable salt or a prodrug thereof;

wherein a dashed line represents the presence or absence of a double bond or a triple bond;


15 A is  $-(CH_2)_6-$ , *cis*  $-CH_2CH=CH-(CH_2)_3-$ , or  $-CH_2C\equiv C-(CH_2)_3-$ , wherein 1 or 2 carbon atoms may be substituted with S or O;

Z is O, S, or NR;

X is selected from the group consisting of  $CO_2H$ ,  $CONHR_2$ ,  $CONR_2$ ,

$CON(OR)R$ ,  $CON(CH_2CH_2OH)_2$ ,  $CONH(CH_2CH_2OH)$ ,  $CH_2OH$ ,  $P(O)(OH)_2$ ,

$CONHSO_2R$ ,  $SO_2NR_2$ ,  $SO_2NHR$ , and




J is  $C=O$  or  $CHOH$ ;

R is independently H,  $C_1-C_6$  alkyl, phenyl, or biphenyl; and


25 E is  $C_3-C_6$  alkyl,  $C_4-C_{10}$  cycloalkyl, phenyl or naphthyl having from 0 to 2 substituents, or a heteroaromatic moiety having from 0 to 2 substituents, wherein said substituents comprise up to 4 non-hydrogen atoms.

2. The compound of claim 1 comprising



5 or a pharmaceutically acceptable salt or a prodrug thereof.

3. The compound of claim 1 comprising



or a pharmaceutically acceptable salt or a prodrug thereof.

4. The compound of claim 3 wherein Z is O.

10 5. The compound of claim 3 wherein Z is S.

6. The compound of claim 3 wherein Z is NH.

7. The compound of claim 3 wherein J is C=O.


8. The compound of claim 3 wherein J is CHOH.

9. The compound of claim 3 wherein X is CO<sub>2</sub>H.

15 10. The compound of claim 3 wherein E is phenyl, thienyl, furyl, pyridinyl, naphthyl, benzothienyl, or benzofuryl having from 0 to 2 substituents comprising up to 4 non-hydrogen atoms.

11. The compound of claim 3 wherein E is *n*-butyl.


12. The compound of claim 1 comprising



20


or a pharmaceutically acceptable salt or a prodrug thereof.

13. The compound of claim 1 comprising




or a pharmaceutically acceptable salt or a prodrug thereof.

14. The compound of claim 1 comprising



or a pharmaceutically acceptable salt or a prodrug thereof.

10 15. A liquid composition comprising



or a pharmaceutically acceptable salt or a prodrug thereof;


wherein a dashed line represents the presence or absence of a double bond or a triple bond;

15 A is  $-(CH_2)_6-$ , *cis*  $-CH_2CH=CH-(CH_2)_3-$ , or  $-CH_2C\equiv C-(CH_2)_3-$ , wherein 1 or 2 carbon atoms may be substituted with S or O;

Z is O, S, or NR;

X is selected from the group consisting of  $CO_2H$ ,  $CONHR_2$ ,  $CONR_2$ ,  $CON(OR)R$ ,  $CON(CH_2CH_2OH)_2$ ,  $CONH(CH_2CH_2OH)$ ,  $CH_2OH$ ,  $P(O)(OH)_2$ ,

20  $CONHSO_2R$ ,  $SO_2NR_2$ ,  $SO_2NHR$ , and



5

J is C=O or CHOH;


R is independently H, C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, or biphenyl; and

E is C<sub>3</sub>-C<sub>6</sub> alkyl, C<sub>4</sub>-C<sub>10</sub> cycloalkyl, phenyl or naphthyl having from 0 to 2 substituents, or a heteroaromatic moiety having from 0 to 2 substituents, wherein

10 said substituents comprise up to 4 non-hydrogen atoms;

wherein said liquid is formulated for ophthalmic use.

16. A method comprising administering a compound to a mammal, wherein said method is useful for the treatment of glaucoma or ocular hypertension in said mammal, said compound comprising



15

or a pharmaceutically acceptable salt or a prodrug thereof;

wherein a dashed line represents the presence or absence of a double bond or a triple bond;

A is  $-(CH_2)_6-$ , *cis*  $-CH_2CH=CH-(CH_2)_3-$ , or  $-CH_2C\equiv C-(CH_2)_3-$ , wherein 1 or 2 carbon atoms may be substituted with S or O;


20

Z is O, S, or NR;

X is selected from the group consisting of CO<sub>2</sub>H, CONHR<sub>2</sub>, CONR<sub>2</sub>,

CON(OR)R, CON(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, CONH(CH<sub>2</sub>CH<sub>2</sub>OH), CH<sub>2</sub>OH, P(O)(OH)<sub>2</sub>,

CONHSO<sub>2</sub>R, SO<sub>2</sub>NR<sub>2</sub>, SO<sub>2</sub>NHR, and



25

J is C=O or CHOH;

R is independently H, C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, or biphenyl; and

- 5 E is C<sub>3</sub>-C<sub>6</sub> alkyl, C<sub>4</sub>-C<sub>10</sub> cycloalkyl, phenyl or naphthyl having from 0 to 2 substituents, or a heteroaromatic moiety having from 0 to 2 substituents, wherein said substituents comprise up to 4 non-hydrogen atoms.